The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: SemBioSys Genetics Inc.

Monday Biotech Deal Review: October 4, 2010

This week’s Monday Deal Review brings you the usual assortment of biotech wheelings and dealings from the past week, including a summary of the newly completed Valeant / Biovail merger.  Read more of this post

Monday Biotech Deal Review: September 27, 2010

Welcome to your Monday Biotech Deal Review. I am very excited to be writing for The Cross-Border Biotech Blog after working with Jeremy behind the scenes over the past three years. [ed. welcome (back) aboard!] It was a busy week for Canadian biotech companies, so let’s get started. Read more of this post

Monday Biotech Deal Review: January 25, 2010

Everyone’s looking to the future in this week’s deal review: two special committees, 225,000 options, two royalty streams, a delisting notice and the first income trust/tax loss deal of 2010.  Read more of this post

Monday Biotech Deal Review: December 21, 2009

This week’s deal review shows no signs of a holiday showdown.  In Canada, BioMS’ deal with Spectral Diagnostics was interesting as a possible indicator of more to come and internationally, 5 new pharma deals were announced this morning including a $430 million deal that OncoGenex landed from Teva joining new links between Athersys and Pfizer, Lilly and Incyte, sanofi-aventis and Chattem and Seattle Genetics and GSK.  Check out the past week’s Canadian deal-making (and breaking) after the jump…

Monday Biotech Deal Review: November 23, 2009

A slightly delayed Deal Review this week because of some non-biotech deal activity.  Live, from New York, it’s the Deal Review!

Read more of this post

Monday Biotech Deal Review: November 2, 2009

B&W_BigNickelIn this week’s Deal Review: SemBioSys hops on the SIFT Tax bandwagon; new deals from Microbix, OPMEDIC and GeneNews; and good updates from iCo Therapeutics, QLT, Noveko and Oncolytics. Read more of this post

Monday Biotech Deal Review: October 25, 2009

B&W_BigNickelA very busy deal week coincided with a very busy work week (for those of us with day jobs), so allow me a particularly grateful thank-you to Jacob Cawker, who’s been an invaluable help with the Deal Review this and the last several weeks.  After the jump, licenses both inbound, outbound and just tied up (optioned); securities extended and accelerated (plus an actual common share offering, with the word “units” banished for one special week); and last but not least, a good volume of Canadian M&A (M&Eh?) from private to public to “just browsing.”  Read more of this post

Monday Deal Review: August 3, 2009

B&W_BigNickelHopefully, the Deal Review will be a longer list as the newly-launched Ontario Emerging Technologies Fund starts deploying some capital, but for this week, the Canadian deal front was pretty quiet.   A few developments, like the JLL-Patheon pathos and the milestone for Cardiome from Merck, were noted at the time in our Twitter stream @crossborderbio, and aside from that there are only a few deals, and a bit of bad news, to check out  after the jump…

Monday Deal Review: July 27, 2009

B&W_BigNickelWell, July is wrapping up with no sign of summer, or of the summer doldrums.  Read on for all the rainy-day deals we found this week after the jump…

Monday Deal Review: June 22, 2009

B&W_BigNickelA whole gaggle of securities deals, a cluster of licenses and a flock of M&A all migrate back to Canada for summer in this week’s Monday Deal Review.  Plus, a deal that may improve the medical isotope shortage.   after the jump…

Monday Deal Review: May 11, 2009

bignickel1Check out the latest Patheon-JLL developments, a licensing deal that looks like a subcontracting arrangement, a plan of arrangement M&A that looks like a license, and the rest of the Canadian deal info from this past week after the jump…

Monday Deal Review: April 6, 2009

One complex arrangement, two clinical trial updates, three commercial deals and other bits of Canadian deal and company miscellany after the jump…

Friday Science Review: March 20, 2009

I had a hard time finding news-making Canadian science stories this week; but in the meantime, here’s a  “numbers” edition of the Friday Science Review:

  • Number of Canadians with cancer: Statistics Canada released its latest figures, showing that of all persons living in Canada on January 1, 2005, 695,000 had been diagnosed with an invasive cancer at some point in the previous 10 years.  That includes the 1 in every 111 women diagnosed with breast cancer, and the 1 in every 118 men diagnosed with prostate cancer.  The headline number shows an increase in the number of Canadians living with cancer; but that’s due to the earlier detection of cancer and improving survival.
  • Number of Canadians who could be helped by nanotech packaging: 11 million Canadians suffer from food-borne illnesses, some of which could be prevented by rapid nanoparticle-based testing.  Nanoparticles could also be used in packaging to signal when food has passed its best-before date.
  • Number of centimeters long you have to be to qualify as the “T-Rex of the Cambrian Period”: twenty.  At the time, most creatures were no bigger than a fingernail … although how could you tell, since there were no fingernails at the time?!? (har.)
  • Number of mussels needed to make a tube of a new medical adhesive: mussels don’t make adhesive, people make adhesive.  Duh.  Here’s a cool story, though, about a new adhesive based on a protein that marine mussels use to stick to rocks.
  • Number of volunteers needed for a 3-way crossover study to show bioequivalence: twenty-three, at least for SemBioSys Genetics Inc.’s trial of its plant-produced human insulin.

Bookmark and Share

Follow

Get every new post delivered to your Inbox.

Join 129 other followers